1. Clinical & Scientific Overview
Vitamin C (Ascorbic Acid) (TIP-MED-000195, Reference Code [10.11]) is classified under
Vitamins, Minerals & Nutritional Supplements (Ch 10) as a Water-Soluble Antioxidant Vitamin & Reducing Cofactor (Prolyl/Lysyl Hydroxylase Collagen Synthesis & Non-Haem Iron Absorption Enhancer).
Within the Indian regulatory and compendial framework, it is governed under Non-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommended for High-Dose/Therapeutic Regimens).
Representative Indian Market Examples (Edition 2.7 Ch 10 [10.11], p. 132): Celin 500 (GSK/Koye), Limcee 500 Chewable (Abbott), Sukcee — Strengths & Dosage Forms: Oral Uncoated & Chewable Tablets: 500 mg (Sodium Ascorbate + Ascorbic Acid in chewable formulations); Drops: 100 mg/mL; Parenteral Injection: 500 mg/5 mL
Oral Uncoated & Chewable Tablets: 500 mg (Sodium Ascorbate + Ascorbic Acid in chewable formulations); Drops: 100 mg/mL; Parenteral Injection: 500 mg/5 mL
3. Mechanism of Action & Pharmacodynamics
Water-Soluble Antioxidant Vitamin & Reducing Cofactor (Prolyl/Lysyl Hydroxylase Collagen Synthesis & Non-Haem Iron Absorption Enhancer) acting on target receptor/enzyme pathways in Vitamins, Minerals & Nutritional Supplements (Ch 10): clinical efficacy is mediated via Water-Soluble Antioxidant Vitamin & Reducing Cofactor (Prolyl/Lysyl Hydroxylase Collagen Synthesis & Non-Haem Iron Absorption Enhancer) for Prevention and treatment of Vitamin C deficiency (scurvy: gingival bleeding, perifollicular petechiae, poor wound healing); adjunct to Oral Iron therapy (reduces ferric Fe3+ to absorbable ferrous Fe2+ in the duodenum); promotion of postoperative, burn, and pressure-ulcer collagen healing; methaemoglobinaemia adjunct..
4. Therapeutic Indications & Evidence-Supported Uses
- Prevention and treatment of Vitamin C deficiency (scurvy: gingival bleeding, perifollicular petechiae, poor wound healing)
- adjunct to Oral Iron therapy (reduces ferric Fe3+ to absorbable ferrous Fe2+ in the duodenum)
- promotion of postoperative, burn, and pressure-ulcer collagen healing
- methaemoglobinaemia adjunct
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: Iron Absorption Enhancer / Wound Healing / Convalescence: 250 mg to 500 mg once daily (up to 500 mg twice daily for 1–2 weeks in acute scurvy or severe wounds; note that intestinal SVCT1 active transport saturates above 200–500 mg, with excess excreted in urine). Follow physician prescription.
Administration & Meal Timing: With or without food; when prescribed alongside Oral Iron, take AT THE EXACT SAME TIME as the Iron tablet! | Once daily in the morning or mid-morning (or with the daily iron dose).
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Strictly limit dose in Chronic Kidney Disease! In CKD Stages 4–5 and dialysis, oxalic acid formed from high-dose Vitamin C (≥500–1000 mg/day) cannot be excreted and deposits in kidneys, bones, and myocardium (systemic oxalosis)—do not exceed 60–100 mg/day in advanced CKD! Hepatic: Avoid high doses in iron-overload liver disease.
Renal: Strictly limit dose in Chronic Kidney Disease! In CKD Stages 4–5 and dialysis, oxalic acid formed from high-dose Vitamin C (≥500–1000 mg/day) cannot be excreted and deposits in kidneys, bones, and myocardium (systemic oxalosis)—do not exceed 60–100 mg/day in advanced CKD! Hepatic: Avoid high doses in iron-overload liver disease.
Renal: Strictly limit dose in Chronic Kidney Disease! In CKD Stages 4–5 and dialysis, oxalic acid formed from high-dose Vitamin C (≥500–1000 mg/day) cannot be excreted and deposits in kidneys, bones, and myocardium (systemic oxalosis)—do not exceed 60–100 mg/day in advanced CKD! Hepatic: Avoid high doses in iron-overload liver disease.
7. Contraindications, Precautions & High-Risk Warnings
- Contraindicated or avoid high doses (>500 mg/day) in patients with a history of Calcium Oxalate Kidney Stones (Nephrolithiasis), Hyperoxaluria, Chronic Kidney Disease (Stages 4–5 / Dialysis), G6PD Deficiency, and Iron Overload (Thalassaemia Major / Haemochromatosis)!
Key Clinical Precautions: Renal: Strictly limit dose in Chronic Kidney Disease! In CKD Stages 4–5 and dialysis, oxalic acid formed from high-dose Vitamin C (≥500–1000 mg/day) cannot be excreted and deposits in kidneys, bones, and myocardium (systemic oxalosis)—do not exceed 60–100 mg/day in advanced CKD! Hepatic: Avoid high doses in iron-overload liver disease.
8. Adverse Effects Profile
- Mild heartburn/epigastric acidity, osmotic loose stools/diarrhoea (only at megadoses >2000 mg/day), dental enamel erosion if acidic chewable tablets are chewed repeatedly without rinsing mouth.
- Calcium Oxalate Nephrolithiasis (Kidney Stones) and Oxalate Nephropathy (unabsorbed/excess Ascorbic Acid is metabolised endogenously to Oxalate and excreted in urine—precipitating calcium oxalate crystals in renal tubules!), acute haemolysis in G6PD deficiency (with high IV/oral doses), worsening cardiac/hepatic iron toxicity in thalassaemia.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Enhances Oral Iron Absorption by 30% (beneficial in IDA, hazardous in thalassaemia)
- Enhances intestinal Aluminium absorption from aluminium antacids (avoid combining in CKD!)
- High doses (>1000 mg/day) can cause false-negative stool occult blood tests and false readings on certain amperometric blood glucometer strips! Acidifies urine, which can accelerate renal excretion of basic drugs (amphetamines) and increase crystalluria with sulfonamides
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: 1. If prescribed with an Iron tablet for anaemia, take the Vitamin C tablet together with the Iron tablet to boost iron absorption. 2. Rinse mouth with water after chewing chewable Vitamin C tablets to protect dental enamel. 3. Warn patients not to take 500 mg–1000 mg Limcee/Celin tablets indefinitely every day for months 'for immunity', especially if they have a history of kidney stones or weak kidneys, as excess Vitamin C turns into oxalate stones in the urine!
- Meal & Clock Timing Instruction: With or without food; when prescribed alongside Oral Iron, take AT THE EXACT SAME TIME as the Iron tablet! (Once daily in the morning or mid-morning (or with the daily iron dose).)
- Missed Dose Protocol: Skip if missed; never double.
- Geriatric Dispensing Pearl: Screen out chronic megadose Vitamin C habits in elderly CGHS patients with CKD or urolithiasis.
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Uncoated & Chewable Tablets: 500 mg (Sodium Ascorbate + Ascorbic Acid in chewable formulations); Drops: 100 mg/mL; Parenteral Injection: 500 mg/5 mL
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 10 [10.11] (p. 132)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [10.4] Multivitamins and Multiminerals — Comprehensive Micronutrient Supplement (Fat-Soluble Vitamins A, D
- [10.5] Calcium Carbonate (Typically Combined with Vitamin D3) — Inorganic Calcium Salt (40% Elemental Calcium—Highest Elemental Y
- [10.6] Calcium Citrate / Calcium Citrate Malate (CCM) — Organic Acid-Independent Soluble Calcium Salt (~21–24% Elemental
- [10.9] Zinc (Zinc Sulphate Monohydrate / Zinc Acetate / Zinc Gluconate) — Essential Trace Element Cofactor (>300 Metalloenzymes: DNA/RNA Po